PLEDGE 03

  • What's involved: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
  • Take part: Suspended
  • Principal Investigator: Dr Maura Corsetti
Research Theme | Gastrointestinal & Liver

What's involved

A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis

Principal Investigator

Dr Maura Corsetti

Take part

Suspended
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute